Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer
Roivant Sciences Ltd. Common Shares · PHARMACEUTICAL PREPARATIONS · Now $29.09
+15% in 1d after detection
Post-detection moves
1h
—
1d
+15%
3d
+6.2%
7d
+6.3%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS